Soligenix, Inc. received a Nasdaq delisting notice for failing to meet the minimum bid price requirement, with 180 days to regain compliance. Concurrently, the company terminated its HyBryte™ development program for cutaneous T-cell lymphoma following a Phase 3 futility recommendation. Soligenix is now evaluating all strategic options, including M&A opportunities and advancing its other pipeline programs like dusquetide for Behçet’s Disease.

Fulcrum Therapeutics, Inc. has approved a restructuring plan, reducing its workforce by approximately 85% and incurring $4.2 million in charges, following the discontinuation of pociredir for sickle cell disease. Concurrently, Fulcrum has initiated a comprehensive review of strategic alternatives to maximize stockholder value, engaging Leerink Partners LLC as its financial advisor. Potential options include a merger, acquisition, business combination, or sale/licensing of assets.

Fulcrum Therapeutics, Inc. announced the discontinuation of its pociredir program, which was being developed for the treatment of sickle cell disease. Concurrently, the company initiated a comprehensive review of strategic alternatives aimed at maximizing stockholder value.

Genprex announced positive clinical data from its Acclaim trials for Reqorsa® Gene Therapy (quaratusugene ozeplasmid) in lung cancer, presented at the 2026 ASCO Annual Meeting. The data showed that high Trop-2 levels and low PTEN levels correlated with prolonged Progression Free Survival (PFS) in Non-Small Cell Lung Cancer (NSCLC) patients treated with Reqorsa. These identified biomarkers may help predict patient response and enable targeted patient selection for precision medicine.

Genprex announced positive preclinical data for its diabetes gene therapy, GPX-002 (Pdx1/MafA gene therapy), presented at the ASGCT Annual Meeting. The data demonstrated that the therapy reversed hyperglycemia and improved beta-cell function and maturation in Type 2 diabetic mouse models. This preclinical success is considered a pivotal step towards a potentially transformative treatment for T2D, aiming for long-term glycemic control by directly addressing beta-cell dysfunction.

Werewolf Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2026, via a press release furnished as Exhibit 99.1 to this Form 8-K. The company specified that this financial information is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.

Enhabit, Inc. is providing supplemental disclosures to its proxy statement for the pending acquisition by Anchor Parent, LLC, an affiliate of Kinderhook Industries, LLC. This action addresses three stockholder lawsuits and demand letters alleging misrepresentations and omissions in the proxy statement regarding financial projections, valuation analyses, and conflicts of interest. The company aims to mitigate litigation risks and avoid delays to the merger, which is scheduled for a stockholder vote on May 12, 2026.

Genprex, Inc. announced that the Israel Patent Office granted a patent for Reqorsa® Gene Therapy (quaratusugene ozeplasmid) for use in combination with PD-1 antibodies for cancer treatment. This expands Genprex's intellectual property portfolio globally, building on existing patents in major markets. Reqorsa is initially being developed for lung cancer, with preclinical studies showing complementarity with targeted drugs and immunotherapies.

Passage Bio, Inc. announced a workforce restructuring plan on April 28, 2026, as part of its ongoing review of strategic alternatives to maximize shareholder value. The plan involves reducing its workforce by approximately 75% to decrease operating expenses. The company expects to incur approximately $3.3 million in severance and exit costs, primarily in the second quarter of 2026.

Genprex announced positive preclinical data for its diabetes gene therapy candidate, GPX-002 (Pdx1/MafA gene therapy), to be presented at the 2026 ASGCT Annual Meeting. The data demonstrated that GPX-002 reversed hyperglycemia in Type 2 diabetic mouse models by enhancing beta-cell function and maturation. This compelling evidence suggests the technical translatability of the approach for long-term glycemic control in T2D.

Masimo Corporation issued supplemental disclosures to its definitive proxy statement regarding its merger with Danaher Corporation. These disclosures aim to address shareholder litigation and demand letters alleging inadequate information, thereby mitigating risks of delaying the merger. The supplements detail Masimo's prior exploration of strategic alternatives in 2023, where it engaged advisors and contacted potential acquirors, including Danaher, but received no definitive bids, and the subsequent targeted sale process in late 2025 that led to the current merger agreement.

Genprex announced a new Sponsored Research Agreement with The University of Texas MD Anderson Cancer Center to study TROP2 and PTEN biomarkers that may predict patient response to Reqorsa® Gene Therapy, its lead candidate for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The company also provided updates on its Phase 1/2 Acclaim-1 (NSCLC) and Acclaim-3 (SCLC) clinical trials, reporting positive safety profiles and early signs of efficacy, including prolonged progression-free survival and partial responses in some patients.

Passage Bio, Inc. announced updated interim Phase 1/2 clinical trial data for PBFT02 in frontotemporal dementia caused by progranulin deficiency (FTD-GRN), showing reductions in whole brain and frontotemporal cortex atrophy, stabilization of plasma NfL levels, and robust increases in CSF progranulin. The company has initiated a review of strategic alternatives, including M&A, asset sales, or partnerships, and engaged Wedbush PacGrow as a financial advisor. The FDA indicated a randomized controlled registrational study is required for PBFT02, which the company is evaluating due to ethical, logistical, and financial challenges.